Summary
Program for Appropriate Technology in Health (PATH) is a healthcare organization that develops and delivers vaccines and devices to collaborative programs with communities. The organization provides services in the areas of HIV and AIDS, influenza, malaria and tuberculosis. It develops diagnostics for HIV and other sexually transmitted infections, malaria, tuberculosis, diabetes and neglected tropical diseases. PATH also serves in the areas of maternal and child health, vaccines and immunization, and reproductive health. The organization has its presence in Belgium, Cambodia, China, Congo, Ethiopia, France, Ghana, India, Kenya, Peru, South Africa, Switzerland, Thailand, and the US. PATH is headquartered in Seattle, Washington, the US.
Program for Appropriate Technology in Health - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Program for Appropriate Technology in Health, Medical Devices Deals, 2010 to YTD 2016 9
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Janssen Enters Into Licensing Agreement With PATH For Rilpivirine 12
CMC Biologics Enters into Agreement with Path Malaria Vaccine Initiative 14
Affinivax Enters into Development Agreement with PATH for Pneumococcal Disease 15
Mymetics Enters into Co-Development Agreement with Path Malaria Vaccine Initiative 16
Novavax Amends Co-Development Agreement With PATH 17
Scandinavian Biopharma, PATH and University of Gothenburg Amend Agreement to Develop ETEC 18
Liquidia Technologies Extends Co-Development Agreement With PATH 19
Path Malaria Vaccine Initiative And Inovio Pharma Partner To Accelerate Malaria Vaccine Development And Delivery Technologies 20
Novavax Enters Into Co-Development Agreement With PATH 22
PATH Malaria Vaccine Initiative Enters Into An Agreement With Crucell And GlaxoSmithKline 24
Liquidia Technologies Enters Into An Agreement With Path Malaria Vaccine 26
Medicago Enters Into Research Collaboration With PATH 27
Mucosis Enters Into Collaboration With PATH 28
Inovio Pharma Amends Agreement With Path Malaria Vaccine Initiative For DNA Vaccine 29
Glythera Enters Into Research Agreement With PATH MVI 30
PATH MVI Enters Into Co-Development Agreement With JHSPH and Sabin Vaccine Institute 31
Program for Appropriate Technology in Health - Key Competitors 32
Key Employees 33
Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36
List of Tables
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Key Facts 1
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Program for Appropriate Technology in Health, Deals By Therapy Area, 2010 to YTD 2016 8
Program for Appropriate Technology in Health, Medical Devices Deals, 2010 to YTD 2016 9
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Janssen Enters Into Licensing Agreement With PATH For Rilpivirine 12
CMC Biologics Enters into Agreement with Path Malaria Vaccine Initiative 14
Affinivax Enters into Development Agreement with PATH for Pneumococcal Disease 15
Mymetics Enters into Co-Development Agreement with Path Malaria Vaccine Initiative 16
Novavax Amends Co-Development Agreement With PATH 17
Scandinavian Biopharma, PATH and University of Gothenburg Amend Agreement to Develop ETEC 18
Liquidia Technologies Extends Co-Development Agreement With PATH 19
Path Malaria Vaccine Initiative And Inovio Pharma Partner To Accelerate Malaria Vaccine Development And Delivery Technologies 20
Novavax Enters Into Co-Development Agreement With PATH 22
PATH Malaria Vaccine Initiative Enters Into An Agreement With Crucell And GlaxoSmithKline 24
Liquidia Technologies Enters Into An Agreement With Path Malaria Vaccine 26
Medicago Enters Into Research Collaboration With PATH 27
Mucosis Enters Into Collaboration With PATH 28
Inovio Pharma Amends Agreement With Path Malaria Vaccine Initiative For DNA Vaccine 29
Glythera Enters Into Research Agreement With PATH MVI 30
PATH MVI Enters Into Co-Development Agreement With JHSPH and Sabin Vaccine Institute 31
Program for Appropriate Technology in Health, Key Competitors 32
Program for Appropriate Technology in Health, Key Employees 33
Program for Appropriate Technology in Health, Other Locations 34
Program for Appropriate Technology in Health, Subsidiaries 35
List of Figures
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Program for Appropriate Technology in Health, Medical Devices Deals, 2010 to YTD 2016 9
